Invivyd (IVVD) AI Stock Analysis

• Market Cap: $695.58M
• Dividend Yield: N/A
• Average Volume (3M): 4.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: 332.71%
• EPS Growth: 75.73%
• Country: US
• Employees: 99
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 277,122,830
• 10 Day Avg. Volume: 2,380,273
• 30 Day Avg. Volume: 4,163,595
• PEG Ratio: 0.01
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 2.07
• P/FCF Ratio: -0.31
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: 2.10
• Enterprise Value/Gross Profit: 2.25
• Enterprise Value/Ebitda: -1.79
• 1Y Price Target: $10.00
• Price Target Upside: 298.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.23
• Revenue Forecast (FY): $137.70M

• Rating: 56 Neutral
• Price Target: $2.50 ▼(-0.40% Downside)

The score is held back primarily by large ongoing losses and heavy free-cash-flow burn despite strong gross margins and revenue growth. Offsetting that, the balance sheet leverage is low and recent funding/cash updates plus regulatory momentum (Fast Track; pivotal trial initiation) improve execution runway, while technical signals are only moderately supportive and valuation remains constrained by negative earnings.

Positive Factors

High gross margins & strong revenue growth

Sustained ~93% gross margins and rapid top-line growth imply attractive unit economics for antibody products. Durable product-level profitability supports margin scalability as volumes grow and underpins funding of development and commercialization over the next several quarters.

Ample near-term liquidity from financing

A strengthened cash position following multiple financings materially extends operational runway to fund pivotal trials and commercial buildouts. This reduces immediate refinancing risk and allows focused execution on registrational studies and launch preparedness over the coming 2–6 months.

Regulatory and clinical advancement

Fast Track designation plus initiation of a randomized pivotal Phase 3 materially de-risks the regulatory pathway and can accelerate review if results are positive. This structural progress increases the probability of a commercial pathway and long-term product optionality.

Negative Factors

Severe cash burn

Persistent negative operating and free cash flow requires ongoing external funding to sustain R&D and commercialization. Over a multi-quarter horizon this increases dilution and constrains strategic flexibility if commercial ramp or trial readouts underperform expectations.

Large ongoing operating losses

Deep, recurring operating losses indicate the business has not yet reached scale to cover fixed costs. Without sustained revenue expansion or margin improvement, profitability remains distant, keeping shareholder value exposed to further dilution or capital raises.

Revenue exposure to public-health dynamics

Demand for prophylactic antibodies is structurally tied to variant circulation, government buying, and regulatory labeling. That dependence can produce durable revenue volatility and makes long-term sales visibility contingent on epidemiology and public procurement decisions.

Invivyd Business Overview & Revenue Model

Company Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

How the Company Makes Money

Invivyd generates revenue primarily through the development and commercialization of its therapeutic products. The company invests in research and development to create proprietary monoclonal antibodies that can be licensed or sold to healthcare providers, pharmaceutical companies, or directly to the market. Revenue streams may include product sales, licensing agreements, and potential partnerships or collaborations with other pharmaceutical companies. These partnerships can involve co-development or co-marketing arrangements, which can significantly contribute to the company's earnings by leveraging shared resources and expertise.

Invivyd Financial Statement Overview

Summary

Invivyd faces substantial financial challenges with significant losses and negative cash flows, despite recent revenue generation. While the balance sheet shows low leverage and strong cash reserves, consistent operational losses and cash flow inefficiencies pose considerable risks. Strategic improvements are critical for future stability.

Income Statement

Invivyd's financial performance shows a challenging trajectory. The company recorded its first revenue of $25.38 million in 2024 after having no revenue in previous years, indicating a significant growth. However, the company still faces substantial net losses, with a negative net profit margin due to high operational costs. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

Invivyd maintains a relatively strong equity position with a moderate debt load, as evidenced by a low debt-to-equity ratio. However, there has been a significant decrease in stockholders' equity over the years, and the equity ratio has declined, indicating potential risks if losses continue. The company's high cash reserves provide some financial stability.

Cash Flow

The company's cash flow situation is strained, with consistently negative free cash flow due to high operational cash outflows. The free cash flow to net income ratio remains unfavorable, indicating that the company is not generating cash from its operations. However, there is a positive trend in financing activities which have supported cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.04M	25.38M	0.00	0.00	0.00	0.00
Gross Profit	46.71M	23.77M	0.00	0.00	0.00	0.00
EBITDA	-58.49M	-173.76M	-205.75M	-225.80M	-219.41M	0.00
Net Income	-59.86M	-169.93M	-198.64M	-241.32M	-226.79M	-111.98M
Balance Sheet
Total Assets	139.16M	129.51M	229.18M	383.17M	620.09M	117.38M
Cash, Cash Equivalents and Short-Term Investments	84.97M	69.35M	200.64M	371.99M	591.42M	114.99M
Total Debt	2.68M	1.30M	2.17M	3.72M	0.00	0.00
Total Liabilities	46.09M	61.98M	51.71M	27.20M	62.07M	182.63M
Stockholders Equity	93.07M	67.54M	177.47M	355.97M	558.02M	-65.25M
Cash Flow
Free Cash Flow	-80.44M	-170.63M	-173.78M	-221.69M	-184.82M	-14.57M
Operating Cash Flow	-80.29M	-170.49M	-173.16M	-219.99M	-184.74M	-14.57M
Investing Cash Flow	-150.00K	-140.00K	280.68M	-230.67M	-50.71M	0.00
Financing Cash Flow	58.53M	39.33M	1.04M	506.00K	662.68M	129.56M

Invivyd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVVD, the sentiment is Positive. The current price of 2.51 is above the 20-day moving average (MA) of 2.48, above the 50-day MA of 2.25, and above the 200-day MA of 1.25, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 53.17 is Neutral, neither overbought nor oversold. The STOCH value of 12.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IVVD.

Invivyd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IVVD	56 Neutral	$695.58M	―	-67.94%	―	332.71%	75.73%
DSGN	55 Neutral	$522.93M	-7.73	-29.83%	―	―	-40.26%
RCKT	52 Neutral	$419.90M	-1.73	-74.88%	―	―	18.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LRMR	47 Neutral	$287.58M	-1.74	-78.24%	―	―	-67.41%
FDMT	47 Neutral	$417.09M	-1.85	-45.38%	―	―	―

Invivyd Corporate Events

Invivyd Reports Strong PEMGARDA Growth and Advances VYD2311

On January 8, 2026, Invivyd reported preliminary fourth-quarter 2025 net product revenue of $17.2 million from its COVID-19 prophylactic antibody PEMGARDA (pemivibart), reflecting 25% year-over-year and 31% sequential growth, and said year-end 2025 cash and cash equivalents stood at $226.7 million following more than $200 million in second-half financing, strengthening its capacity to fund late-stage development and commercialization efforts. The company highlighted the December 2025 initiation of DECLARATION, a Phase 3 pivotal trial of its vaccine-alternative antibody VYD2311 for COVID prevention, which already has U.S. FDA Fast Track designation, and detailed pipeline expansion with the nomination of potential best-in-class RSV antibody VBY329 for pediatric prophylaxis and ongoing discovery work on ultra-long half-life RSV and measles antibodies, underscoring Invivyd’s bid to establish monoclonal antibody prophylaxis as a new standard of care and broaden its footprint in large, fast-growing infectious disease markets.

The most recent analyst rating on (IVVD) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Invivyd’s COVID Antibody VYD2311 Receives FDA Fast Track

On December 23, 2025, Invivyd announced that the U.S. Food and Drug Administration granted Fast Track designation to VYD2311, its investigational vaccine-alternative monoclonal antibody designed to prevent COVID in individuals with underlying risk factors for severe disease. The designation could accelerate regulatory review for VYD2311, which is being evaluated in DECLARATION, a pivotal Phase 3 randomized, triple-blind, placebo-controlled trial enrolling about 1,770 adults and adolescents—with and without risk factors—to test single and monthly intramuscular dosing over three months, with top-line data expected in mid-2026; the program underscores Invivyd’s push to secure a stronger position in the COVID prevention market as an antibody-based alternative to vaccines, potentially broadening options for high-risk and general populations if efficacy and safety are confirmed.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Invivyd Unveils Promising RSV Antibody Candidate

On November 24, 2025, Invivyd, Inc. announced the selection of VBY329, a potential best-in-class monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in newborns, infants, and children. VBY329, developed using Invivyd’s proprietary technology, shows higher potency and improved resistance compared to existing RSV treatments. The company aims for IND readiness by the second half of 2026, targeting the growing pediatric RSV prophylaxis market, which is expected to reach $3-$4 billion globally by 2030. This development could significantly enhance Invivyd’s industry positioning by providing a novel solution in a rapidly expanding market.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Invivyd Raises $117.2 Million in Public Offering

On November 17, 2025, Invivyd, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 44,000,000 shares of common stock and pre-funded warrants for 6,000,000 shares, raising approximately $117.2 million. The proceeds will support the commercial preparedness for VYD2311, ongoing research and development, and other corporate purposes, potentially impacting the company’s market position and stakeholders.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Invivyd Reports Strong Q3 Growth and FDA Clearance

On November 6, 2025, Invivyd reported its third-quarter financial results, highlighting a 41% year-over-year growth in PEMGARDA revenue and a strengthened cash position following a public offering. The company announced the FDA clearance for its VYD2311 clinical program, which includes pivotal trials expected to start by the end of 2025. Invivyd aims to secure its position as a leader in providing antibody protection against COVID-19 and is preparing for the potential commercial launch of VYD2311. Additionally, the company is exploring pipeline expansion beyond COVID-19, targeting other infectious diseases like RSV and measles.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Invivyd Highlights Antibody Development in New Presentation

On October 30, 2025, Invivyd, Inc. released an investor presentation highlighting their ongoing efforts in antibody development for viral threats, particularly COVID-19. The presentation underscored the challenges posed by COVID-19 variants and the company’s strategic focus on monoclonal antibodies to address these challenges. Invivyd’s initiatives aim to enhance the durability and effectiveness of antibody-based treatments, reflecting their commitment to overcoming the limitations of current vaccines and addressing stakeholder concerns about vaccine efficacy and safety.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.